Close Menu

Agilent

Population Genetics was formed to commercialize the IP portfolio of Sydney Brenner focused on high sensitivity and high specificity NGS detection.

This week's news on Quest Diagnostics, Agilent Technologies, Meridian Bioscience, Era7, DermTech, and Source Molecular.

The test is now CE marked for use in identifying patients with urothelial cancer who are most likely to benefit from Opdivo therapy.

The investment bank took note of Danaher's soft organic growth rate in the first quarter, and said it will need to build up its life science portfolio. 

The companies will work together to develop a next-generation sequencing-based kit version of Agendia's molecular breast cancer diagnostics.

The firm saw 6 percent growth in its life sciences and applied markets group and 13 percent growth in its diagnostics and genomics group during the quarter.

The BRCA Mastr Plus Dx assay and Mastr Reporter software identifies mutations in the coding regions of the BRCA1 and BRCA2 genes

The test can now be used to identify patients with squamous cell carcinoma of the head and neck who are likely to benefit from Opdivo therapy.

Collaborators have created an atlas that compares available PD-L1 IHC assays and reveals areas of debate, including challenges encountered by clinicians.

Pages

The first reported coronavirus cases in Europe and the US might not be related to the subsequent outbreaks in those areas, according to the New York Times.

According to NPR, there's a growing shortage of machines to run SARS-CoV-2 tests.

The Wall Street Journal and Kaiser Health News report that antibody testing for SARS-CoV-2 has led to further confusion.

In Nature this week: the largest known collection of human genetic variants, and more.